VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Arthritis Rheumatol. 2016 Jan;68(1):46-55.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol. 2016 Jan;68(1):46-55.
Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]
Arthritis Research & Therapy (2015) 17:319 DOI: 10.1186/s13075-015-0835-7
Annals of the Rheumatic Diseases. 2015 Sep 9. doi:10.1136/annrheumdis-2014-207201
N Engl J Med 2015;373:1318–28. doi: 10.1056/NEJMoa1503824
Brodalumab treatment resulted in a rapid reduction in the signs and symptoms of PsO. The median time to a PASI 75 response with 210 mg of brodalumab Q2W was 4 weeks, approximately twice as fast as the median time to a response with ustekinumab.
Modern Rheumatology. 2015 Sep 10:1-9. [Epub ahead of print]
Clinical Therapeutics. 2015:37(8). [Epub ahead of print]
Annals of the Rheumatic Diseases. 2015 Aug 5. doi:pii: annrheumdis-2015-207784. 10.1136/annrheumdis-2015-207784. [Epub ahead of print]
Rheumatology. 2015 Aug 4. doi:pii: kev251. [Epub ahead of print]
Annals of the Rheumatic Diseases. 2015 Aug 14. doi:pii: annrheumdis-2014-207178.